Our cutting-edge electronic PRO (ePRO) solutions ensure your clinical trials generate high-quality, reliable evidence to support regulatory approvals and demonstrate real-world patient benefits
The liver fat reductions in the Phase 2 hepatic substudy were also notably larger than those seen with pure GLP-1 agonism
It inhibits melanin formation: It functions by inhibiting tyrosinase, an enzyme, which as a result causes inhibition of melanin a pigment that causes dark pigmentation and an uneven skin tone
BPC-157 is not FDA-approved for human use
If A1C levels remain above goal after three months of therapy, a second agent should be added (e.g., sulfonylurea, thiazolidinedione, dipeptidyl-peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, insulin)